JPMorgan Chase & Co. Increases Apellis Pharmaceuticals (NASD

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price lifted by JPMorgan Chase & Co. from $78.00 to $79.00 in a research note published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. A number of other brokerages also recently issued reports on APLS. Robert W. […]

Related Keywords

Robertw Baird , James George Chopas , Adamj Townsend , Apellis Pharmaceuticals , Nasdaq , Citigroup , Jefferies Financial Group , Needham Company , First Horizon Advisors Inc , Stephens Consulting , Jpmorgan Chase Co , Analyst Recommendations For Apellis Pharmaceuticals , Us Bancorp , Covestor Ltd , Apellis Pharmaceuticals Inc , Apellis Pharmaceuticals Stock Down , Apellis Pharmaceuticals Company Profile , Institutional Investors Weigh In On Apellis Pharmaceuticals , Wealth Management Inc , Securities Exchange Commission , News Ratings For Apellis Pharmaceuticals Daily , Free Report , Financial Group , Moderate Buy , Pharmaceuticals Stock Down , Get Free Report , George Chopas , Exchange Commission , Horizon Advisors , Apellis Pharmaceuticals Daily ,